<i>In vitro</i> models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of <scp>CRISPR</scp> perturbationsElysia C. Saputra, Aleksandra Olow, Federica Piccioni et al.|Molecular Oncology|2025Cited by 1
Supplementary Table S2 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1Suchitra Natarajan, Xin Yu, Elysia C. Saputra et al.|Unknown|2026Cited by 0
Supplementary Table S1 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1Suchitra Natarajan, Xin Yu, Aleksandra Olow et al.|Unknown|2026Cited by 0
Data from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1Suchitra Natarajan, Xin Yu, Aleksandra Olow et al.|Unknown|2026Cited by 0
Supplementary Figure S4 from Targeting AEBP1 to Mitigate Protumor Activity of Cancer-Associated Fibroblasts and Increase Therapeutic Efficacy of Anti–PD-1Suchitra Natarajan, Xin Yu, Aleksandra Olow et al.|Unknown|2026Cited by 0